Sultan F Alnomasy
Overview
Explore the profile of Sultan F Alnomasy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alawadi Z, Alsultan A, Alsallami D, Alnomasy S, Alqasmi M, Almufarriji F, et al.
Open Vet J
. 2024 Jul;
14(6):1417-1425.
PMID: 39055761
Background: is one of the serious pathogens causing various infections in the animal field, such as neonatal calf diarrhea, which is responsible for mortality associated with diarrhea during the first...
2.
Alkhaibari A, Albalawi A, Shater A, Almohammed H, Alnomasy S, Alanazi A
Acta Trop
. 2024 Jul;
257:107312.
PMID: 38972561
This research aimed to produce and analyze zinc oxide nanoparticles (ZNPs) loaded with linalool (LZNPs), and to evaluate their in vitro and in vivo efficacy through targeting the inflammation and...
3.
Althafar Z, Al-Gabri N, Alnomasy S
Int Immunopharmacol
. 2024 May;
135:112249.
PMID: 38772297
Interleukin-35 (IL-35) is a novel anti-inflammatory component, and its role in protecting against acute kidney disease (AKD) has not been explored. Thymoquinone (TQ) has been widely used for many therapeutic...
4.
Majeed Q, Alnomasy S, Shater A, Alanazi A
Acta Parasitol
. 2024 Apr;
69(2):1201-1211.
PMID: 38634986
The present experimental survey designed to green synthesis, characterization, as well as in vitro and in vivo anti-Toxplasma gondii activity of silver nanoparticles (SLN) green synthesized by Lupinus arcticus extract....
5.
Alanazi A, Alnomasy S
Pharmaceuticals (Basel)
. 2023 Nov;
16(11).
PMID: 38004439
Background: Nowadays, interest in the use of nanotechnology for medical purposes is increasing. The current experimental investigation is planned for the green synthesis, characterization, and efficacy of copper nanoparticles (CLN)...
6.
Alanazi A, Majeed Q, Alnomasy S, Almohammed H
Trop Med Infect Dis
. 2023 Jul;
8(7).
PMID: 37505651
Methods: MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to evaluate the in vitro effect of the SLME on tachyzoites. Totally, 72 male BALB/c mice (40 mice for in vivo evaluation of...
7.
Al Shehri Z, Alanazi A, Alnomasy S
Molecules
. 2023 Feb;
28(4).
PMID: 36838959
Background: Hepatocellular carcinoma (HCC) is the most common form of liver cancer that occurs in hepatocytes. Although many chemical drugs, e.g., cisplatin, methotrexate, taxis, and doxorubicin are used to treat...
8.
Alruwaili N, Zafar A, Alsaidan O, Yasir M, Mostafa E, Alnomasy S, et al.
Drug Deliv
. 2022 Sep;
29(1):3035-3050.
PMID: 36120935
Quercetin (QT) is a flavonoid that exhibits anti-oxidant and chemo-preventive activity. This research work aimed to develop surface-modified bilosomes (BS) of QT. The BS was prepared by the solvent evaporation...
9.
Alnomasy S, Alotaibi B, Aldosari Z, Mujamammi A, Alzamami A, Anand P, et al.
Comb Chem High Throughput Screen
. 2022 Aug;
26(6):1196-1203.
PMID: 35975856
Background: SARS-CoV-2 emerged in late 2019 and caused COVID-19. Patients treated with Zyesami were found to have a 3-fold decrease in respiratory failure and improved clinical outcomes. It was reported...
10.
Hanna A, Hamouda H, Goda H, Sadik M, Moghanm F, Ghoneim A, et al.
Bioinorg Chem Appl
. 2022 Mar;
2022:9072508.
PMID: 35265106
The world faces a challenge with the pervasion of multidrug-resistant bacteria that encourages scientists to develop and discover alternative, ecofriendly, and easy-to-produce new antibacterial agents. Our work is part of...